Working with government and policy makers

Working with the UK government, policy makers and regulatory bodies is essential to ensure that patients in the UK can access innovative medicines when they need them.

Healthcare reform and budget changes can have a huge impact on how the NHS delivers its services.

To ensure our medicines can continue to have the biggest possible impact on improving health, we work collaboratively with all areas of government and regulatory bodies.

We want our treatments to improve the lives of as many people as possible.

That goal calls for us to be prominent in all discussions with government on healthcare reform. Ensuring patients encounter fewer barriers to treatment is essential.

Working closely with the government, we aim to provide a valuable perspective on how healthcare policies impact the lives of real people. As a leading UK based company, we are also keen to ensure that the environment for developing new medicines in the UK remains strong, and that the UK can retain its status a centre of medical innovation. We work with our industry trade body, the Association of the British Pharmaceutical Association to ensure that the voice of our industry is part of these important debates.

Examples of who we work with:

  • MPs 
  • NHS bodies
  • Public Health bodies
  • Civil servants
  • Department of Health
  • NICE
  • Association of the British Pharmaceutical Industry
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • National Institute for Biological Standards and Controls